MPN and thrombosis was hard enough . . . now there's COVID-19 thrombosis too.
Hematology Am Soc Hematol Educ Program
; 2021(1): 710-717, 2021 12 10.
Article
in English
| MEDLINE | ID: covidwho-1566502
ABSTRACT
Both myeloproliferative neoplasms (MPNs) and coronavirus disease 2019 (COVID-19) are characterized by an intrinsic thrombotic risk. Little is known about the incidence and the outcome of thrombotic events in patients with MPN infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but common mechanisms of coagulation activation, typical of both disorders, suggest that these patients can be at particularly high risk. To define the best thromboprophylaxis and treatment regimens in both MPN and COVID-19, individual- and disease-specific thrombotic risk factors, bleeding risk, and concomitant specific treatments need to be considered. In this case-based review, an individualized approach is presented in a case of SARS-CoV-2 infection occurring in a man with polycythemia vera (PV). A primary anticoagulant thromboprophylaxis strategy and adjustment of his PV treatment were implemented. However, during the hospital stay, he experienced pulmonary embolism and therapeutic anticoagulation had to be set. Then his condition improved, and discharge was planned. Postdischarge decisions had to be made about the type and duration of venous thromboembolism treatment as well as the management of PV-specific drugs. The steps of our decisions and recommendations are presented.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Polycythemia Vera
/
Thrombosis
/
COVID-19
/
Myeloproliferative Disorders
Type of study:
Case report
/
Observational study
/
Prognostic study
Topics:
Long Covid
Limits:
Aged
/
Humans
/
Male
Language:
English
Journal:
Hematology Am Soc Hematol Educ Program
Journal subject:
Hematology
Year:
2021
Document Type:
Article
Affiliation country:
Hematology.2021000315
Similar
MEDLINE
...
LILACS
LIS